局部晚期食管鳞癌患者癌组织SATB1和PRKDC蛋白表达与放化疗敏感性的关系

doi:10.3969/j.issn.1004-616x.2025.04.015

Abstract

Abstract: OBJECTIVE： To study the expressions of special-AT-rich sequence binding protein-1(SATB1) and catalytic subunit of the DNA-dependent protein kinase(PRKDC) protein in advanced esophageal squamous cell carcinomas and their relationship with carcinomas—sensitivity to chemoradiotherapy. METHODS： Thirty patients with locally advanced esophageal squamous cell carcinoma in our hospital were selected as the study subjects. These patients received standard radical radiotherapy and synchronous chemotherapy. Three months after the completion of chemoradiotherapy，the short-term efficacy was evaluated according to the Criteria (RECIST) which classified the patients into two groups： radiotherapy sensitive group (CR+PR) of 16 cases and a chemoradiotherapy insensitive group (SD+PD) of 14 cases. Simultaneously， clinical data such as patient gender，age，pathological grading，clinical staging，tumor location，and survival status were collected. Western Blot assay was used to detect the expression levels of SATB1 and PRKDC proteins in cancer tissues of the patients. Relationships between the expression levels and clinical pathological factors were determined. RESULTS： The PRKDC protein was not expressed in both the sensitive and insensitive groups of carcinomas. Expression levels of SATB1 were higher in the sensitive than the insensitive group (P<0.05). Compared with the insensitive group，the sensitive group had lower tumor differentiation and earlier staging (P<0.05). There was no statistically significant difference in gender，age，lesion location，and 1-year survival between the sensitive and the insensitive groups (P>0.05). CONCLUSION： Our data shows that expression of the SATB1 protein was closely related to the sensitivity of esophageal carcinomas to chemoradiotherapy and to the degree of differentiation. The expression may therefore be useful in predicting efficacy of esophageal carcinomas to chemoradiotherapy. On the other hand，PRKDC protein was not expressed in the cancer tissues.

Key words: SATB1, PRKDC, esophageal cancer, chemoradiosensitivity

CLC Number:

R730.5

AYIGULI·Hare, ABUDILI·Abuduxuku. Expression of SATB1 and PRKDC proteins and sensitivity of advanced esophageal squamous cell carcinomas to chemotherapy[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 314-318.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 徐玥, 廖应英, 孙泽群. 食管癌的流行病学特征及发病高危因素研究进展[J]. 中国现代医生, 2024, 62(7): 113-117.
[3] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
[4] ZHOU B L, BIE F L, ZANG R C, et al. Global burden and temporal trends in incidence and mortality of oesophageal cancer[J]. J Adv Res, 2023, 50: 135-144.
[5] SOHDA M, ISHIKAWA H, MASUDA N, et al. Pretreatment evaluation of combined HIF-1alpha, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer[J]. Int J Cancer, 2004, 110(6): 838-844.
[6] SUN S F, CHENG S G, ZHU Y X, et al. Identification of PRKDC (protein kinase, DNA-activated, catalytic polypeptide) as an essential gene for colorectal cancer (CRCs) cells[J]. Gene, 2016, 584(1): 90-96.
[7] ZHOU Y, LIU F, XU Q Y, et al. Inhibiting importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer[J]. Oncogene, 2020, 39(34): 5633-5648.
[8] SUN-G, YANG-L, DONG-C, et-al. PRKDC regulates chemosen-sitivity and is a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients[J]. Oncol Rep, 2017, 37(6): 3536-3542.
[9] SIEGEL M J, IPPOLITO J E, WAHL R L, et al. Discrepant assessments of progressive disease in clinical trials between routine clinical reads and formal RECIST 1.1 interpretations[J]. Radiol Imaging Cancer, 2023, 5(5): e230001.
[10] KOBAYASHI Y, SUGIURA T, IMAJYO I, et al. Knockdown of the T-box transcription factor Brachyury increases sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation in vitro: implications for a new therapeutic principle[J]. Int J Oncol, 2014, 44(4): 1107-1117.
[11] WANG J, YU P Y, LUO J D, et al. Transcriptomic and microRNA expression profiles identify biomarkers for predicting neo-chemoradiotherapy response in esophageal squamous cell carcinomas (ESCC)[J]. Front Pharmacol, 2021, 12: 626972.
[12] MEZENCEV R, MATYUNINA L V, JABBARI N, et al. Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity[J]. BMC Cancer, 2016, 16: 236.
[13] ZHANG L, KIM S, JIA G X, et al. Exome sequencing of normal and isogenic transformed human colonic epithelial cells (HCECs) reveals novel genes potentially involved in the early stages of colorectal tumorigenesis[J]. BMC Genomics, 2015, 16(Sup 1): S8.
[14] CAI S T, HAN H J, KOHWI-SHIGEMATSU T. Tissue-specific nuclear architecture and gene expression regulated by SATB1[J]. Nat Genet, 2003, 34(1): 42-51.
[15] PANCHAL O, WICHMANN G, GRENMAN R, et al. SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC)[J]. Sci Rep, 2020, 10(1): 8615.
[16] YE-C-S, ZHOU-D-N, YANG-Q-Q, et al. Silencing SATB1 influences cell invasion, migration, proliferation, and drug resistance in nasopharyngeal carcinoma[J].-Int-J-Clin-Exp-Pathol, 2014, 7(3): 914-922.
[17] 张升, 张士发, 王良民, 等. SIRT1、EZH2和SATB1在皮肤恶性黑素瘤组织中的表达及其临床意义[J]. 临床皮肤科杂志, 2021, 50(3): 138-142.
[18] 龚丹, 瞿伟. E2F5和SATB1在乳腺癌组织中的表达及其对乳腺癌细胞生物学功能的影响[J]. 吉林医学, 2023, 44(5): 1151-1154.
[19] 马博, 周军, 李建刚, 等. SATB1、CBX7表达预测结直肠癌患者术后复发的价值[J]. 中国现代医学杂志, 2022, 32(20): 90-95.
[20] 韦付坤, 阚懿, 刘继海, 等. 特异性核基质结合区结合蛋白1与转录因子E盒结合锌指蛋白1在前列腺癌组织的表达及其临床意义[J]. 中华实验外科杂志, 2021, 38(6): 1067-1070.
[21] 李欢, 董宇曦. AFP、AKT2、SATB1在原发性肝癌患者中的表达水平及与临床病理特征的关系[J]. 国际检验医学杂志, 2022, 43(18): 2274-2278, 2282.
[22] 乔娟, 杨昊, 牛丽红, 等. 干扰SATB1抑制宫颈癌增殖和转移能力及增强宫颈癌放射敏感性的作用研究[J]. 国际检验医学杂志, 2023, 44(21): 2581-2586.
[23] GLATZEL-PLUCI-SKA N, PIOTROWSKA A, DZI-GIEL P, et al. The role of SATB1 in tumour progression and metastasis[J]. Int J Mol Sci, 2019, 20(17): 4156.
[24] JENKE R, HOLZH-USER-REIN M, MUELLER-WILKE S, et al. SATB1-mediated upregulation of the oncogenic receptor tyrosine kinase HER3 antagonizes MET inhibition in gastric cancer cells[J]. Int J Mol Sci, 2021, 22(1): 82.
[25] HUANG B, XIONG F, WANG S W, et al. Effect of SATB1 silencing on the proliferation, invasion and apoptosis of TE-1 esophageal cancer cells[J]. Oncol Lett, 2017, 13(5): 2915-2920.
[26] REN F, YANG Z L, TAN X G, et al. DNA-PKcs and Ku70 are predictive markers for poor prognosis of patients with gall bladder malignancies[J]. Appl Immunohistochem Mol Morphol, 2014, 22(10): 741-747.

Expression of SATB1 and PRKDC proteins and sensitivity of advanced esophageal squamous cell carcinomas to chemotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YANG Zhihui, HAN Xianglong, LIU Gengang, SHI Jie. Relationships between serum Lipocalin-2 and YKL-40 levels on therapeutic effect of neoadjuvant radiotherapy and chemotherapy in esophageal cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(4): 310-313,318.
[2]	ZHAO Liran, BU Liang. Bioinformatics analysis of key gene expression in esophageal cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 374-381.
[3]	FU Jing, LIU Qing, YU Haiye, WANG Lei. Regulation of malignant phenotype of esophageal squamous carcinoma cells by miR-495 via suppressing the expression of RNF113A [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 202-208,214.
[4]	LU Dapeng, ZHAO Weilin, WANG Yuqiang, LU Hongchao, WEI Shuangping. Survival follow-up survey of esophageal cancers and establishment of a nomogram prognosis prediction model [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(1): 37-42.
[5]	FENG Zhiyin, WU Yixian, HA Xiaodan, CHEN Wujin, LI Xiumei, DONG Juanjuan. Detection of p38MAPK gene in plasma cell-free DNA among patients with high incidence of esophageal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 105-109.
[6]	JIAO Wenjing, GUO Xiujuan, MA Ming, SHAO Junguo, ZHANG Jinyan. Comparative efficacies between concurrent chemo-radiotherapy and radiotherapy alone in elderly patients with locally advanced esophageal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 124-128.
[7]	CHEN Wanxian, WANG Simeng, CHEN Zhangyu, WANG Panji, ZHENG Chunwen, LI Enmin, XU Liyan. CASIN, a CDC42 inhibitor, inhibited viability and migration of esophageal carcinoma cells in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 136-142.
[8]	FENG Min, ABBIE·Mohetar, SHI Jingyi, ZUKELAI·Alijiang, LI Yongxiang, YAN Changshun, LI Xiumei. Expression of miR-143, miR-145 and Survivin mRNA in esophageal cancers among Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 29-32.
[9]	MA Lili, ZHANG Shuli, LI Qin, XU Peng, FENG Min, LI Xiumei. Screening and identification of differentially expressed miRNAs in esophageal cancers among Xinjiang Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 52-56.
[10]	YANG Xingxiao, ZOU Naiyi, LI Qiaofang, ZHANG Xueyuan, SONG Heng, LIU Zhikun, MA Ming, SHAN Baoen, ZHU Shuchai. Significance in expression of RNF2 and PCNA proteins in esophageal squamous cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(4): 254-257.
[11]	HE Shuzhi, ZHAO Yue, LIU Yang, YANG Liucai, CHEN Ping, LIU Ran. Evaluation of the quality of life among esophageal cancer patients who received chemotherapy [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 437-444,449.
[12]	LI Xiumei, GUO Qiong, WANG Dong, CHEN Yan, LI Hui, CHEN Hongming, LI Huiwu. Expression and significance of miR-143, MMP-2 and TIMP-1 in esophageal cancer in Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 32-35,40.
[13]	CAO Ying-ya，CHE Yi-qun，CHEN Qun，MA Wen-tao，LIU Yang，HAO Jia-jie，CAI Yan，LU Wei-hua，WANG Ming-rong，ZHANG Yu. Establishment of an esophageal cell line with stable expression of inducible PLK1-shRNA [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(5): 348-352.
[14]	LI Xiu-mei，LI Hui，JIANG Xiao-fang，CHEN Yan，CHEN Hong-ming，LI Hui-wu. Expression of Survivin shRNA interference on CDK4 in esophageal ECA109 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2014, 26(4): 298-304.
[15]	TIAN Wei，ZHANG Hui-xia，CHEN Yan. Methylation of the CpG island in MT-3 gene in esophageal carcinoma in Kazaks and Hans in Xinjiang [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2013, 25(5): 357-359.